United States. Securities and Exchange Commission
Stereotaxis, Inc., a Delaware-based company, has entered into a Tenth Loan Modification Agreement with Silicon Valley Bank to extend the maturity of its revolving credit facility from March 31, 2015, to March 31, 2018. This modification, announced on March 30, 2015, also revises the financial covenants under the agreement to
United States. Securities and Exchange Commission
Zimmer Holdings Inc. has conditionally cleared its proposed acquisition of Biomet, Inc. after the European Commission ("EC") gave its conditional approval. The EC's clearance is contingent upon Zimmer divesting certain assets as part of a remedy package previously submitted. This development follows clearance from the Japan
United States. Securities and Exchange Commission
St Jude Medical Inc. submitted a U.S. Securities and Exchange Commission (SEC) filing on January 28, 2015, indicating the occurrence of material events or corporate changes that had not been previously reported. The filing, marked by Form 8-K, contains seven documents detailing the company's updates. As a
United States. Securities and Exchange Commission
Arrhythmia Research Technology Inc. has filed a Securities and Exchange Commission (SEC) filing SC 13G on January 26, 2015, with the SIC code 3845, Electromedical and Electrotherapeutic Apparatus. The filing contains one document and has the SEC file number 0001157523-15-000195. The company's contact information is provided as 25
Medical equipment industry
Zacks Equity Research, a leader in providing quantitative and qualitative analysis to help investors make informed decisions, has featured several stocks in its Analyst Blog. The latest stocks discussed include American Medical Systems Holdings, Inc. (Nasdaq:AMMD), Laserscope (Nasdaq:LSCP), eBay (Nasdaq:EBAY), Cititrends (Nasdaq:CTRN), and Zumiez (Nasdaq:ZUMZ)
Medical equipment industry
American Medical Systems Holdings, Inc., a Delaware corporation, has agreed to acquire Laserscope, a California corporation, in a cash tender offer valued at $31.00 per share. The acquisition, which is subject to certain conditions, is expected to result in Laserscope becoming an indirect wholly owned subsidiary of American Medical
Pharmaceutical industry
Elliott Associates, a major Guidant shareholder, has come out in favor of Boston Scientific's $25 billion offer, valuing the Indianapolis-based device maker at $72 a share. The move is a critical development in the takeover battle for Guidant, as it marks the first significant endorsement of Boston Scientific&
Pharmaceutical industry
Boston Scientific Corporation has increased its bid for Guidant Corporation, attempting to outmaneuver Johnson & Johnson in a highly competitive bidding war for the heart-device maker. The Natick company's $72-per-share offer, worth approximately $25 billion, includes a definitive agreement to sell Guidant's vascular business to Abbott
Medical equipment industry
Johnson & Johnson's attempted acquisition of Guidant Corp., a leading manufacturer of pacemakers and implantable defibrillators, has encountered a significant obstacle. Boston Scientific Corp. has submitted a higher bid, and Guidant's board of directors has initiated talks with the rival company. This development has sent shockwaves
Medical equipment industry
Boston Scientific Corp. has shaken up the medical device market by submitting a $25 billion bid for Guidant Corp., a maker of implantable heart devices, in a move that could thwart Johnson & Johnson's $21.5 billion acquisition offer. The surprise bid represents a 14 percent premium over
Medical equipment industry
The US Food and Drug Administration's conditional approval of Santa Barbara-based Inamed Corp.'s silicone gel-filled implants marks a significant step towards bringing back the use of silicone breast implants in the US market, which has been banned for the past 13 years due to health concerns.
Medical equipment industry
The Food and Drug Administration (FDA) has given conditional approval to Inamed Corp. for the sale of its silicone gel-filled breast implants, pending the resolution of outstanding safety concerns. This decision comes after the company addressed the primary safety concerns raised by a federal advisory panel in April. The approval
